AlydiaHealth_logo v2.png

3475 Edison Way, Suite J
Menlo Park, CA 94025 USA

CAUTION: Investigational Device. Limited by U.S. law to investigational use.

©2018 by Alydia Health.

MOTHERS DESERVE SAFER CHILDBIRTH

Evidence shows that mothers everywhere, from Sub-Saharan Africa to New York City, are at risk of preventable injury and even death during childbirth.

Join our mission to make childbirth safer for every mother.

Postpartum hemorrhage: 

A leading cause of maternal injury and mortality

Postpartum hemorrhage (PPH) is excessive bleeding following delivery.  PPH is a scary and life-threatening condition, and today’s treatments are not always effective. Mothers experiencing PPH may require blood transfusions, drugs which may cause dangerous side effects, long uncomfortable procedures, and hysterectomy. Sometimes, PPH can be fatal. 

Directly following childbirth, the uterus should contract, which stops the normal bleeding associated with delivery. A mother with risk factors such as a long or challenging delivery might find that her uterus is unable to contract on its own, causing uncontrolled bleeding, referred to as postpartum hemorrhage. 

Coverage of the U.S. maternal safety crisis

May 12, 2017

U.S. Has the Worst Rate of Maternal Deaths in the Developed World

Let's solve this problem

At Alydia Health, we are entirely focused on making childbirth safer for every mother. We have developed a unique device intended to rapidly stop excessive bleeding by encouraging the normal contractions that should happen after childbirth. 

Our device is designed to use gentle suction to collapse an exhausted uterus quickly, and encourage it to contract fully on its own.  This quick procedure is intended to allow a mother to avoid surgery and peacefully connect with her newborn. The device is currently investigational and is the subject of an ongoing clinical trial.

CAUTION: Investigational Device. Limited by U.S. law to investigational use.

 

EARLY CLINICAL RESEARCH

First-in-Woman

In the first ten women treated with Alydia’s device, hemorrhage was controlled within 2 minutes, with no recurrence and with very little blood loss after treatment initiation. 

Purwosunu Y, et al. Obstetrics and Gynecology.

Vol. 128, No.1 (2016):33-36

CURRENT CLINICAL RESEARCH

The PEARLE Study

An IDE clinical study is currently underway at leading U.S. Hospitals to evaluate the safety and effectiveness of Alydia’s investigational device.  Data from this trial is being gathered to support an application for U.S. Food and Drug Administration (FDA) marketing clearance. 

NCT 02883673

Alydia Health in the news

Alydia Banner2.png
Alydia-Banner01.png

Alydia Health was previously known as InPress Technologies

Stay in touch with Alydia Health